IN8bio CEO to Present at H.C. Wainwright Conference Amid Clinical Pipeline Push
Event summary
- IN8bio CEO William Ho to participate in fireside chat at H.C. Wainwright conference on September 14, 2026.
- Management team to host one-on-one investor meetings during the event.
- Company developing gamma-delta T cell therapies for cancer and autoimmune diseases.
- Key pipeline candidates include INB-600 (T cell engager), INB-100 (leukemia treatment), and INB-200/400 (glioblastoma therapy).
The big picture
IN8bio's participation in the H.C. Wainwright conference comes as the biopharmaceutical company seeks to highlight its innovative gamma-delta T cell therapies. The event provides a platform to showcase its clinical pipeline, which includes treatments for high-risk leukemias and glioblastoma, amid growing interest in cellular therapies for oncology and autoimmune indications. The company's ability to attract investor attention will be crucial as it advances its candidates through clinical trials.
What we're watching
- Clinical Progress
- How IN8bio's pipeline advancements will impact investor perception and potential partnerships.
- Market Positioning
- Whether IN8bio can differentiate itself in the competitive gamma-delta T cell therapy space.
- Funding Strategy
- The pace at which IN8bio secures additional funding to support its clinical-stage programs.